Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?

被引:21
作者
de Kok, Inge M. C. M. [1 ]
Habbema, J. Dik F. [1 ]
van Rosmalen, Joost [1 ]
van Ballegooijen, Marjolein [1 ]
机构
[1] Erasmus MC, Univ Med Ctr Rotterdam, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands
关键词
HPV vaccine; Cancer; Benefits and costs; Cost effectiveness; International perspective; HUMAN-PAPILLOMAVIRUS VACCINATION; SQUAMOUS-CELL CARCINOMA; HEALTH-CARE COSTS; SCREENING-PROGRAMS; PARTICLE VACCINE; UNITED-STATES; LAST YEAR; IMPACT; EFFICACY; TYPE-18;
D O I
10.1016/j.ejca.2010.09.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Besides cervical cancer, the human papillomavirus (HPV) is found in other cancers and may be preventable with HPV vaccination. However, these other cancers are often not accounted for in cost-effectiveness analyses of HPV vaccination. This study estimates the potential maximum effect on the cost-effectiveness ratio (CER) of HPV vaccination in preventing non-cervical HPV-positive cancers. For the Dutch situation, a mathematical equation was used to estimate the maximum impact if all cancer cases of the penis, vulva/vagina, anus, oral cavity and oro-pharynx with HPV16/18 are prevented, in terms of number of life years gained, savings and improvement in the CER of the vaccination. For other countries and for future developments, we show how the impact on the CER varies depending on the incidence of cervical/non-cervical HPV 16/18-positive cancers, vaccine costs and clinical costs. If in the Netherlands all HPV 16/18-positive cancers are prevented by vaccination in women only, compared to if only HPV 16/18-positive cervical cancer is prevented, the life years gained increase with 14%, the savings increase with 18%, and the CER decreases with 13%. If vaccination prevents HPV-positive cancers in both men and women, these figures increase to 25%, 26% and 21%, respectively. In conclusion, if HPV vaccination fully prevents all non-cervical HPV-positive cancers, this would substantially increase its cost-effectiveness. The impact of the vaccination varies depending on the incidence of cervical/non-cervical HPV16/18-positive cancers, the vaccine costs and clinical costs. Observed combinations of these parameters in different countries show a decrease in the CER between 10% and 31%. (C) 2010 Published by Elsevier Ltd.
引用
收藏
页码:428 / 435
页数:8
相关论文
共 38 条
  • [1] Cervical cancer screening policies and coverage in Europe
    Anttila, Ahti
    von Karsa, Lawrence
    Aasmaa, Auni
    Fender, Muriel
    Patnick, Julietta
    Rebolj, Matejka
    Nicula, Florian
    Vass, Laszlo
    Valerianova, Zdravka
    Voti, Lydia
    Sauvaget, Catherine
    Ronco, Guglielmo
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (15) : 2649 - 2658
  • [2] Trends of cervical cancer mortality in the member states of the European Union
    Arbyn, Marc
    Raifu, Amidu O.
    Weiderpass, Elisabete
    Bray, Freddie
    Anttila, Ahti
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (15) : 2640 - 2648
  • [3] Cancer Research UK, CANCERSTATS
  • [4] Cost-effectiveness of human papillomavirus vaccination in the United States
    Chesson, Harrell W.
    Ekwueme, Donatus U.
    Saraiya, Mona
    Markowitz, Lauri E.
    [J]. EMERGING INFECTIOUS DISEASES, 2008, 14 (02) : 244 - 251
  • [5] *COLL ZORGV, 2006, RICHTL FARM EC OND G
  • [6] A population-based study of squamous cell vaginal cancer: HPV and cofactors
    Daling, JR
    Madeleine, MM
    Schwartz, SM
    Shera, KA
    Carter, JJ
    McKnight, B
    Porter, PL
    Galloway, DA
    McDougall, JK
    Tamimi, H
    [J]. GYNECOLOGIC ONCOLOGY, 2002, 84 (02) : 263 - 270
  • [7] The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening
    de Kok, I. M. C. M.
    Polder, J. J.
    Habbema, J. D. F.
    Berkers, L-M
    Meerding, W. J.
    Rebolj, M.
    van Ballegooijen, M.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 100 (08) : 1240 - 1244
  • [8] Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands
    de Kok, Inge M. C. M.
    van Ballegooijen, Marjolein
    Habbema, J. Dik F.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (15): : 1083 - 1092
  • [9] Engholm G., 2008, NORDCAN: Cancer Incidence, Mortality and Prevalence in the Nordic Countries
  • [10] Frisch M, 1999, CANCER RES, V59, P753